Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
- Conditions
- Malignant Glioma
- Interventions
- Behavioral: surveys and cognitive tests
- Registration Number
- NCT02023346
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 95
Patient Inclusion Criteria
- Age greater than or equal to 18
- Diagnosis of any WHO grade III or IV glioma
- Admitted to the inpatient Neurology service
- Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in English
Caregiver Inclusion Criteria
- Age greater than or equal to 18
- Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance.
- The patient has himself or herself agreed to participate in this study
Patient Exclusion Criteria
- A patient will be excluded if the Glasgow Coma Scale is less than 15. The patient must be oriented to self, age, place, and year, and month.
- Aphasia precluding comprehension and verbalization of consent to participate
- Patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. This evaluation will take place for otherwise eligible and willing participants, and it will be performed by the NP or MD clinician who is obtaining informed consent and will be documented in the medical record.
Caregiver Exclusion Criteria
- No eligible caregivers who can complete the brief assessment in person or via telephone will be excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Malignant Glioma patients surveys and cognitive tests This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
- Primary Outcome Measures
Name Time Method measure prognostic awareness 2 years Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Memoral Sloan Kettering Cancer Center
🇺🇸New York, New York, United States